MAKLUMAT LANJUT BERKENAAN TRANSFER FACTOR kebaikan untuk anda.

Transfer factor (TF) is an extract of low molecular weight containing several lymphokine molecules with immunomodulating properties. It has been described for the first time by Lawrence in the early ‘50s. It seems capable of transferring antigen-specific information to T-lymphocytes, and it is present in the lymphocytes of mammals and birds. It has been widely used over the past forty years in the treatment of viral, parasitic, fungal infections and allergic disorders, as well as immunodeficiencies, neoplasias, viz. cancer of the lung and prostate. Encouraging clinical results have also been observed in patients suffering from candidiasis and tuberculosis.

It has been thought that the potential of this compound for answering the challenge of unknown pathogenic agents is considerable as is its preventative potential. Data have shown that antigen-specific TF administered before a viral infection can prevent the onset of the disease, TF acting as a preventative vaccine based on cell mediated immunity.

Its molecular structure has only partially been unravelled. It seems that to a small peptide (ca. 5000 DA) are attached 2-3 ribonucleotides. However, this lack of knowledge did not prevent its clinical use since it is possible to produce large quantities of specific transfer factor in tissue culture or in immunised animals.

The first observations postulating the existence and establishing the concept of transfer factor dates from the early 1950s when H.S. Lawrence showed that delayed type hypersensitivity (DTH) to a given antigen could be transferred from one individual to another via cell-free extracts obtained from the leucocytes of an immunised donor. He assumed that this adoptive transfer of immunity was due to a molecule which he named transfer factor and he surmised that its molecular weight was less than 12,000 Daltons, as it filters through a standard dialysis bag. Since that time, all transfer factor preparations for clinical and experimental studies have been obtained by disrupting lymphocytes, dialysing the lysates and using the dialysed material for in vitro tests or in vivo clinical or animal studies.

Over fifteen hundred reports have confirmed Lawrence’s original observations and established that the dialyzable extracts thus obtained are capable of transferring specific immune information in vitro to naïve lymphocytes or in vivo to patients or experimental animals. This information concerns only cell-mediated but not humoral immunity, no de novo antibody production has ever been elicited by transfer factor, although it has been reported that it may modulate normal antibody production triggered by conventional immunisation.

Since the early 70’s, transfer factor has been used more often than not successfully for the treatment of viral, parasitic, fungal infections, and also as an adjuvant treatment in autoimmune, allergic and malignant disorders. Its apparent success is of no surprise since cell-mediated immunity (CMI) plays a crucial role in the control of infectious, parasitic, and autoimmune diseases, as well as cancer.

Because the TF extract is usually obtained from the total lymphocyte population containing helper and suppressor lymphocytes, it acts as a modulator of the immune system. It boosts the immune defences when required, e.g. in infectious, malignant or genetically impaired immune disorders or it exerts a suppressing effect on a hyperactive immune system when its down-regulation is desirable, e.g. in allergic disorders.

The mechanism of action of TF remains largely unknown, its activity, in addition to the transfer of immune information, is manifested as a non-specific modulation of the immune response. It is known that the dialyzable extract containing the TF molecules also contains other low molecular weight lymphokines e.g. IMREG 1 and 2. Thus, its non-antigen-specific immunomodulating activity, which may also play a role in the regulation of humoral immunity, is due to molecules present in the dialysate, but distinct from those responsible for the transfer of antigen-specific information.

It seems that the total dialysate obtained from peripheral lymphocytes is a cocktail of molecules that provide immunoregulatory activity, in addition to the adoptive transfer of novel antigenic specificities to the immunological memory of the recipient. Hence the qualification of TF as an immunomodulator, i.e. a lymphokine with immunomodulatory activity mediating adoptive immunity, in contrast with so-called active (antibody induction by immunisation with the corresponding antigen) or passive (mediated by antibody injection) immunity.

Nonetheless, and notwithstanding encouraging clinical results, many drawbacks have impeded research in this field and fast advances in understanding the nature and mode of action of this intriguing biological entity.

Until 1974, the only source of transfer factor was pooled leucocytes from blood donors, which limited material supplies, whereas the biological potency and specific activity of the extract varied from one preparation to another. Indeed, the precise antigenic specificity of the various batches of material used was practically unknown, but presumably large, since each batch reflected the collective immune experience of several individuals. For this reason, these preparations were improperly called “non-specific”, indicating multiple but unknown specificities.

Thus, despite several encouraging reports in the early 1970s, the clinical use of transfer factor was curtailed by the dearth of material with standardised and consistent activity. Similarly, biochemical studies were virtually impossible for lack of sufficient raw material for purification. In 1974, Viza and co-workers reported that TF with known specificities could be replicated in tissue culture, using a lymphoblastoid cell line. In the late 1970s, the same group and other investigators presented evidence that specific TF obtained from mammals after immunisation with a given antigen was also active in humans.

Nevertheless, in spite of the resolution of the supply problem, the controversy relating to this molecule was to grow. There are several reasons for this, and they pertain mainly to its unusual characteristics.

Nearly fifty years after Lawrence’s original observations, transfer factor remains an elusive and controversial entity, despite enormous laboratory efforts and several clinical studies with encouraging and sometimes spectacular results. Biochemical studies have already produced evidence that the molecule responsible for the transfer of the antigenic specificity is a small peptide with a molecular weight of approximately 5000 DA, and it has been suggested that two to three ribonucleotides are attached to the peptide. Unfortunately, attempts at sequencing the peptide have failed, because of the presence of a blocked amino terminus.

The transfer of antigen-specific CMI information by this extract is thought provoking, for it apparently contravenes essential tenets of immunology and molecular biology. However, since the experimental evidence supporting the antigen-specific transfer is uncontested, various hypotheses for understanding its mechanism have been proposed, but so far none has proven totally acceptable.

The specificity issue thus remains one of the essential problems. TF dialysates contain non-specific immunoregulatory molecules which can usually enhance and, in certain cases, down-regulate CMI. Two such molecules named IMREG I and IMREG II were identified by Gottlieb and his co-workers. Nevertheless, such moieties could play a role in enhancing a weak response to a ubiquitous antigen and thus provide false evidence of specific transfer. Studies undertaken with such rare antigens as coccidioidin or keyhole limpet haemocyanin (KLH) preclude non-specific enhancement of “lapsed” immunological memory. Several human and animal studies have established that TF is capable of transferring CMI to rare antigens that the recipient is unlikely to have encountered by chance.

The overall picture became more complex when two types of antigen-specific activity were described within the dialysates: a) inducer or helper activity, which is the activity of the conventional transfer factor and b) anti-transfer factor or suppressor activity. The distinctive properties of the two entities are as follows: transfer factor binds to its related antigen, suppressor factor binds to the related antibody (IgG); inducer factor is absorbed by T suppressor cells and macrophages, whereas suppressor factor is absorbed by T-helper cells and macrophages; inducer factor derives from T-helper cells, suppressor factor from T-suppressor cells.

Be that as it may, TF’s characteristics (low molecular weight, undefined chemical structure, unconventional mode of action, protein-like nature but resistant to most proteolytic enzymes) together with its biological properties (non-species specificity, transfer of antigen-specific information) have generated more opponents than supporters. And the frustration resulting from unsuccessful attempts to solve this multi-faceted riddle, especially the failure so far to unravel the molecular structure, apparently due to a blocked amino terminus of the peptide forbidding its sequence by conventional methods, has led scientists to doubt its very existence.

Despite promising results and hundreds of publications, failure to explain TF’s mechanism of action and define its molecular structure aroused doubts about its very existence. And even though recent work by Kirkpatrick has partially determined an amino-acid sequence (LLYAQDLEDN), thus giving some biochemical reality to the elusive moiety, no further publication has confirmed and complemented these data since.

Moreover, the pharmaceutical industry did not pay sufficient attention to this moiety because of the prohibitive costs of bringing a new medicine onto the market and the lack of patent protection (the impossibility of filing patents after decades of published academic work). In addition, the difficulties involved in production made commercialisation unviable. And a compound producing such astounding results as those described in the scientific literature, and which has not been on the market for so many years, gradually begins to lose its credibility. As for the commercial preparations obtained from colostrums and today sold via the internet, they definitely decrease the credibility of the product. Their acclaimed effects have never been tested or confirmed independently, neither in vitro nor in vivo, and the alleged clinical improvements cannot thus be differentiated from a placebo effect.

Even if some clinical reports of the ‘70s are subject to justified criticism, hundreds of studies have established the efficacy of transfer factor in treating several pathologies. Its lack of toxicity and the absence of side effects made the use of this extract appealing. Moreover, despite current scepticism, no publication has ever rejected reported clinical claims. An impressive number of clinical studies have demonstrated the efficacy of transfer factor in treating and even preventing viral infections. For instance, Steele and co-workers were able to protect leukaemic children receiving chemotherapy from varicella zoster virus infections using varicella-zoster-specific transfer factor. In the early 1980s, Viza and Dwyer described significant improvement obtained by the use of herpes-simplex-virus-specific transfer factor in treating patients suffering from recurrent genital and/or labial herpes. The clinical observations were later corroborated by experiments in a mouse model.

Other clinical studies have shown that specific transfer factor may produce a spectacular improvement in acute cytomegalovirus (CMV) infections. Moreover, in Africa, children suffering from Burkitt’s lymphoma (a tumour caused by EBV) treated over a long period with EBV-specific TF showed a significant decrease in the rate of relapses. Other viral infections e.g. hepatitis B respond equally well to specific TF.

Transfer factor treatment has proven to be helpful in several neoplasias. One should cite the pioneering work of Fudenberg and that of Pizza. Osteosarcoma, melanoma, breast, lung, prostate and kidney cancer patients have benefited from TF therapy.

Parasitic infections also respond to TF therapy as the data of Sharma, confirmed by Delgado, in treating cutaneous leishmaniasis suggest. Other parasitic diseases known to respond effectively to TF are schistosomiasis and cryptosporidiosis, and several reports cite positive results obtained in treating patients with mycobacterial infections such as lepromatus leprosy, mycobacterium fortuitum pneumonia refractory to antibiotic therapy and tuberculosis. Chronic mucocutaneous candidiasis, an immunodeficiency characterized by chronically relapsing Candida albicans infections also responds well to TF treatment.

HUBUNGI SAYA UNTUK MAKLUMAT LEBIH LANJUT DI= 0163153132(Zaidah)016-3143695 (AYIM)

___________________________________________________________________________________________________

A SHORT BIBLIOGRAPHY

Ablashi DV, Levine PH, De Vinci C, Whitman JE Jr, Pizza G, Viza D: Use of anti HHV-6 transfer factor for the treatment of two patients with Chronic Fatigue Syndrome (CFS). Two case reports. Biotherapy 1996; 9: 81-86.

Bilello P, Fishman M, Koch G: Evidence that immune RNA is messenger RNA. Cell Immunol 1976; 23: 309.

Boucheix C, Phillips J, Pizza G, Sartorio C, Viza D: Activity of animal transfer factor in man. Lancet 1977; i: 189-99.

Burger DR, Vandenbark AA, Dunnic W, Kraybill WG, Vetto RM: Properties of human transfer factor from KLH-immunized donors: Dissociation of dermal transfer and proliferation augmenting activities. J Reticuloendothel Soc 1976; 24: 385-402.

Chang Y, Cesarman E, Pessin MS et al.: Identification of herpesvirus-like DNA sequences in AIDS-associated Kaposi’s sarcoma. Science 1994; 266: 1865-1869.

Delgado O, Romano EL, Belfort E, Pifano F, Scorza JV, Rojas Z: Dialyzable leukocyte extract therapy in immunodepressed patients with cutaneous leishmaniasis. Clin Immunol Immunopathol 1981; 19: 351-358.

Dwyer JM: The use of antigen-specific transfer factor in the management of infections with herpes viruses. In: C.H. Kirkpatrick et al. (eds.) Immunobiology of Transfer Factor. Academic Press, New York 1983: 233-243.

Fernandez-Ortega C, Dubed M, Ruibal O, Vilarrubia OL, Menendez de San Pedro JC, Navea L, Ojeda M, Arana MJ: Inhibition of in vitro HIV infection by dialysable leucocyte extracts. Biotherapy 1996; 9: 33-40.

Fudenberg HH, Fudenberg HL: Transfer factor: Past, present and future. In E. Jucker (ed.): Annual Review of Pharmacology and Toxicology. Birkhäuser Verlag, Basel, Switzerland 1989: 475-516.

Fudenberg HH, Levin AS, Spitler LE, Wybran J, Byers V: The therapeutic uses of transfer factor. Hosp Pract 1974; 9: 95-104.

Fujisawa T, Yamaguchi Y: Postoperative immunostimulation after complete resection improves survival of patients with stage 1 nonsmall cell lung carcinoma. Cancer 1996; 78: 1892-1898.

Galbraith GMP, Fudenberg HH: Transfer factor. In: J. Stone (ed.) : Dermatologic Immunology and Allergy. Mosby, St. Louis, Mo 1985: 889-98.

Gottlieb AA, Sizemore RC, Gottlieb MS, Kern CH: Rationale and clinical results of using leucocyte-derived immunosupportive therapies in HIV disease. Biotherapy 1996; 9: 27-31.

Griscelli C, Revillard JP, Betuel H, Herzog C, Touraine JL: Transfer factor therapy in immunodeficiencies. Biomedicine 1973; 18: 220-227.

Hastings RC, Morales MJ, Shannon EJ, Jacobson RR: Preliminary results in the safety and efficacy of transfer factor in leprosy. In: M.S. Asher, A.A. Gottlieb, C.H. Kirkpatrick (eds.): Transfer Factor: Basic Properties and Clinical Applications. Academic Press, New York 1976: 465-76.

Kirkpatrick C.H, Transfer Factors: Identification of Conserved Sequences in Transfer Factor Molecules. Mol Med 2000; 6(4): 332-341. Kirkpatrick CH, Greenberg LE: Treatment of chronic mucocutaneaous candidiasis with transfer factor. In: A. Khan, C.H. Kirkpatrick, N.O. Hill (eds.): Immune Regulators in Transfer Factor. Academic Press, New York 1979: 547-62.

Lawrence HS, Borkowsky W: Transfer Factor – Current status and future prospects. Biotherapy 1996; 9: 1-5.

Lawrence HS: The transfer in humans of delayed skin sensitivity to streptococci M substance and to tuberculin with disrupted leukocytes. J Clin Inv 1955; 34: 219-32.

Lesser PG, Margarido L, Bolda W, Sartori SG, Hares WA, Freire CA, Fleury R, Montenegro MR, Leser W, Naspitz CK: Cell-mediated immunity in patients with Virchowian Hanseniasis before and after treatment with transfer factor. Hansenol Int J 1980; 5(1); 3-27-34.

Levin AS, Byers VS, Fudenberg HH et al.: Osteogenic sarcoma: Immunologic parameters before and during immunotherapy with tumor specific transfer factor. J Clin Invest 1975; 55: 487-499.

Levin AS, Spitler LE, Stites DP, Fudenberg HH: Wiskott-Aldrich syndrome, a genetically determined cellular immunologic deficiency: clinical and laboratory response to therapy with transfer factor. PNAS 1970; 67: 821.

Masi M, De Vinci C, Baricordi OR: Transfer factor in chronic mucocutaneaous candidiasis. Biotherapy 1996; 9: 97-103.

McMeeking A, Borkowski W, Klesius PH, Bonk S, Holzman RS, Lawrence HS: A controlled trial of bovine dialyzable leukocyte extract for cryptosporidiosis in patients with AIDS. J Infec Dis 1990; 161: 108-12. Meduri R, Campos E, Scorolli L, De Vinci C, Pizza G, Viza D: Efficacy of transfer factor in treating patients with recurrent ocular herpes infections. Biotherapy 1996; 9: 61-66.

Metcalf JF, John JF Jr, Wilson GB, Fudenberg HH, Harley RA: Mycobacterium-fortuitum pulmonary infection associated with an antigen-selective defect in cellular immunity. Am J Med 1981; 71: 485-491.

Neequaye J, Viza D, Pizza G, Levine PH, De Vinci C, Ablashi DV, Biggar RJ, Nkrumah F: Specific transfer factor with activity against Epstein-Barr virus reduces late relapse in endemic Burkitt’s lymphoma. Anticanc R 1990; 10: 1183-1187.

Nkrumah F, Pizza G, Viza D, Phillips J, De Vinci C, Levine P: Regression of progressive lymphadenopathy in a young child with acute CMV infection following the administration of transfer factor with specific anti-CMV activity. Lymphok Res 1985; 4: 237-241.

Pilotti V, Mastrorilli M, Pizza G, DeVinci C, Busutti L, Palareti A, Gozetti G, Cavallari A: Transfer factor as an adjuvant to non-small cell lung cancer (NSCLC) therapy. Biotherapy 1996; 9: 117-121.

Pizza G, Chiodo F, Colangeli V, Gritti F, Raise E, Fudenberg HH, De Vinci C, Viza D: Preliminary observations using HIV-specific transfer factor in AIDS. Biotherapy 1996; 9: 41-47.

Pizza G, De Vinci C, Cuzzocrea D, Menniti D, Aiello E, Maver P, Corrado G, Romagnoli P, Dragoni E, LoConte G, Riolo U, Palareti A, Zucchelli P, Fornarola V, Viza D: A preliminary report on the use of transfer factor for treating stage D3 hormone-unresponsive metastatic prostate cancer. Biotherapy 1996; 9: 123-132.

Pizza G, Viza D, De Vinci C, Palareti A, Cuzzocrea D, Fornarola V, Baricordi R: Orally administered HSV-specific transfer factor (transfer factor) prevents genital or labial herpes relapses. Biotherapy 1996; 9: 67-72.

Pizza G, Viza D, Roda A, Aldini R, Roda E, Barbara L: Transfer factor for the treatment of chronic active hepatitis. N Eng J Med 1979; 300: 1332.

Prasad U, bin Jalaludin MA, Rajadurai P, Pizza G, De Vinci C, Viza D, Levine PH: Transfer factor with anti-EBV activity as an adjuvant therapy for nasopharyngeal carcinoma: A pilot study. Biotherapy 1996; 9: 109-115.

Rappaport FT, Lawrence HS, Millar JW, Pappagianis D, Smith CE: Transfer of delayed hypersensitivity to coccidioidin in man. J Immunol 1960; 84: 358-67.

Sharma MK, Anaraki F, Ala F: Preliminary results of transfer factor therapy of persistent cutaneous leishmania infection. Clin Immunol Immunopathol 1979; 12: 183-190.

Spitler LE, Levin AS, Stites DP, Fudenberg HH, Pirofsky B, August CS, Stiehm ER, Hitzig WH, Gatti RA: The Wiskott-Aldrich syndrome. Results of transfer factor therapy. J Clin Invest 1972; 51: 3216-24.

Steele WR, Myers MG, Vincent MM: Transfer factor for the prevention of varicella zoster infection in childhood leukaemia. N Eng J Med 1980; 303: 355-59.

Steele WR: Transfer factor and cellular reactivity to varicella zoster antigen in childhood leukaemia. Cell Immun 1980; 50: 202-89.

Vich JM, Viza D: Specific suppressor dialysates from mice. In: C.H. Kirkpatrick, D.R. Burger, H.S. Lawrence (eds.): Immunobiology of Transfer Factor. Academic Press, New York 1983: 197-202.

Vich JM, Garcia JV, Engel P, Garcia PA: Transfer to man of sensitization to Keyhole Limpet Haemocyanin by mouse transfer factor. Lancet 1978; i: 265.

Viza D, Goust JM, Moulias R, Trejdosiewicz LK, Collard A, Müllet-Bérat N: In vitro production of transfer factor by lymphoblastoid cell lines. Transplant 1975; VII (suppl. 1): 329-333.

Viza D, Lefesvre A, Patrasco M, Phillips J et al.: A preliminary report on three AIDS patients treated with anti-HIV specific transfer factor. J Exp Path 1987; 3: 653-659.

Viza D, Vich JM, Minarro A, Ablashi DV, Salahuddin SZ: Soluble extracts from a lymphoblastoid cell line modulate SAIDS evolution. J Virol Met 1988; 21: 241-253.

Viza D, Vich JM, Phillips J, Rosenfeld F, Davies DAL: Specific transfer factor protects mice against lethal challenge with herpes simplex virus. Cell Immun 1986; 100: 555-562.

Viza D, Vich JM, Phillips J, Rosenfeld F: Orally administered specific transfer factor for the treatment of herpes infections. Lymphok Res 1985; 4: 27-30.

Wilson GB, Metcalf JF Jr, Fudenberg HH: Treatment of mycobacterium-fortuitum pulmonary infection with “transfer factor” (TF): New methodology for evaluating TF potency and predicting clinical response. Clin Immunol Immunopathol 1982; 23: 478-483.

BERMINAT UNTUK MENCUBA TRANSFER FACTOR?

HUBUNGI SAYA UNTUK MAKLUMAT LEBIH LANJUT DI= 0163153132(Zaidah)016-3143695 (AYIM)

4LIFE TRANSFER FACTOR DI AMR(ULASAN PERUBATAN DI AMERIKA)

SEKIRANYA BERMINAT UNTUK MENCUBA,SILA HUBUNGI KAMI SEMULA.

Kolestrol rendah meningkatkan peluang kanser??

Low Cholesterol Levels Increases Cancer Risk- American College of Cardiology

For years, I’ve been telling my patients that the medical establishment’s obsession with lowering cholesterol to prevent heart disease is causing more harm than good.

If your doctor continues to get you worried about your high cholesterol levels, here’s a bit of news for you…

In fact, your high cholesterol may be protecting you from cancer.

Today, I’ll explain the truth behind the myth of cholesterol, and show you how to achieve heart health naturally.

A new study published in the Journal of the American College of Cardiology revealed that driving down cholesterol levels actually increases the risk of cancer.

Researchers at the Tufts University School of Medicine found that among people taking “statin” drugs – like Lipitor and Zocor – there was a higher rate of cancer. Although the link between the drugs and cancer wasn’t clear, there was no doubt that drastically low cholesterol levels correlated to cancer risk.

The big drug makers continue to sell the notion that the best way to fight heart disease is to lower LDL levels, the so-called “bad” cholesterol.

Yet 75 percent of people who suffer heart attacks have normal cholesterol levels.

It makes sense that low cholesterol levels are linked to cancer because cholesterol is one of your body’s basic building blocks. You need it to produce testosterone, to build and repair cell membranes, and to preserve your nerve cells through the formation of the protective “sheaths” that cover them.

Starving your body of this critical substance will lead to other health problems. We already know that extremely low cholesterol levels result in muscle weakness, fatigue, depression, decreased sex drive, and “brain fog.” This new research shows that there may be even more deadly consequences.

What really matters is not low “bad” cholesterol, but high levels of HDL, the so-called “good” cholesterol. As long as you have a high HDL count – 75 to 80, for example – it doesn’t matter whether your total cholesterol is 150 or 350. A high HDL will always keep your risk of heart disease extremely low.

So why haven’t you heard this already? It may be because there’s no drug that effectively raises good cholesterol levels. You can only effectively do it naturally.

Consume natural fats. Avoid processed or fast foods containing “trans” fats – these man-made substances were never meant for consumption, and your body doesn’t know what to do with them. They wind up clogging your arteries and putting you on the fast track to heart disease.

Instead, get your fat from free-range or grass-fed animals, eggs, nuts, and unprocessed vegetable oils. These are some of the healthiest foods you can eat. (As with all foods, look for organic or minimally processed options whenever possible.)

The health benefit of these natural fats comes from their balance of Omega-3 and Omega-6 fatty acids. Your body needs both but, as with cholesterol, they have to be in balance. Omega-3s are great for your heart. They’ve been shown to prevent irregular heartbeat, reduce clogging of the arteries, lower blood pressure, and decrease inflammation in body tissues.
If you stick to eating natural fats, you’ll automatically get the right ratio of Omega-6 and Omega-3, which is about 2:1. As an added bonus, you’ll automatically raise your “good” cholesterol levels and you’ll reduce your risk of cancer.

To Your Good Health,

Al Sears, MD

ILMU KESIHATAN 4LIFE DAN PRODUK 4LIFE

TESTIMONI PENGUNA TRANFER FACTOR DI MALAYSIA DAN SINGAPORE

PENAWAR AJAIB 4 LIFE

SILA CLIK DISINI UNTUK MENDAPAT MAKLUMAT TESTIMONI PENGUNA TRANSFER FACTOR 4LIFE.

New Breakthrough Advances Our Knowledge of Immunity

Richard Bennett, Ph.D.

Applied Life Sciences

At a time when science is just beginning to understand how transfer factors work in the vastly complex communications of the immune system, people throughout the world are reaping the benefits of improved health and immune system function from these amazing molecules.

The work of many researchers demonstrates that transfer factors educate and enhance immunological functions. Highlights of this work include the documentation that natural killer (NK) cell lymphocyte activity significantly increases after a single pulse of transfer factors.

Transfer factors are fundamentally the information molecule of the immune system. In a small portion of the transfer factors peptide (a string of amino acids), the molecular identity of a virus, a bacteria or other pathogen is encoded. At the molecular level, this is analogous to casting a footprint in wet sand; that impression is transfer factor.

When the immune system sees these “footprints,” it grabs them, processes them and hands them off to uncommitted or immature immune cells that do not have a footprint of their own. In the process of grabbing and passing off this information, many cytokines are secreted into the immediate area. In particular, the cytokines interleukin 12 (IL-12) and interleukin 2 (IL-2) provide general excitement and enhancement of all immune cells and the NK cell in particular.

Transfer factors for commercial use were first obtained from the colostrum of dairy cattle. With the subsequent discovery of transfer factors in the yolk of hen’s eggs, science took a big step in the development of transfer factors targeted for specific organs. As hens lay an egg a day, they have become a significant source of transfer factors.

The idea to blend bovine (cow) colostral transfer factors and avian (chicken) transfer factors came from the notion that the two sources of transfer factors from different species may provide a broader array of microbial identities encoded in the transfer factors to educate the immune system in a synergistic fashion.

To test the idea that a blend of transfer factors may further enhance immune function, scientists used the NK cell assay. The NK cell assay is the best test currently available to evaluate immune function. The NK assay uses living lymphocytes in an in vitro, or lab, setting. Using this assay, researchers were able to determine the specific blend of bovine and avian transfer factors that outperformed all the others. The study results exceeded the researchers’ expectations and provided important insights, primarily that it does appear that the blend works synergistically.

What Natural Killer Cells Do Before discussing the test, it is important to understand the function of NK cells in the immune system. Scientists and physicians the world over, are just now recognizing the power of the NK cell to control viral infections and tumors. They use some of the natural immune modulators to attempt to enhance immune function. A great number of studies show very clearly that the NK cell can and does control and help contain many types of cancer and virally-infected cells.

The NK cell is a unique type of lymphocyte as it needs no priming or education to function as the T- and B-lymphocytes do. Rather the NK cell has the ability to recognize foreignness. A tissue transplanted surgically is often rejected by the NK cell unless the tissue “match” is very good and certain immune-suppressing drugs are given. A cell that has transformed into a tumor or a cell that has become infected with a virus may lose its native character and appear foreign to the NK cell.

The NK cells patrol all the cells of the body and make physical contact with the “NK kiss.” If the kiss reveals that the cell is okay and not foreign, the cell is given grace. If the kiss reveals that the cells are a tumor or virally-infected, the kiss is the kiss of death and two types of toxins elaborated by the NK cell destroy the cell.

The NK cell used to be thought of as a primitive form of immunity. It is now very clear that the NK cell is the “king pin” of the immune system and has great influence over many immune functions. Thus, high functioning NK cells have many important roles in maintaining optimal immune function and balance.

Measuring NK Cell Activity White blood cells from healthy donors provided a source of lymphocytes for the assay. Unmarked samples containing several different combinations of transfer factors sourced from cow colostrum and chicken egg yolks were incubated with the NK cells for various time periods of up to 48 hours in order to identify the most potent blend ratio. Known quantities of NK cells are added to small wells containing living cancer cells. These cancer cells are the targets for the NK cells. A dye that can be measured electronically is used to indicate when a cancer cell is lysed, or killed. This allows for objective measurement of the NK cell actions. The test then determines the number of the target cancer cells destroyed by the NK cells. The percent cell lysis (CL) is the important measure.

Natural Killer cell Test Results

(The Cancer Killing Cell)

The NK cell tests for the avian/bovine 4Life Transfer Factor blends and 4Life Transfer Factor Plus blends revealed the optimal blends that induced the NK cells to kill 69 and 97% of the cancer cells, respectively (Figure 1). This represents a 283 and 437% increase over baseline, or control NK cell function, where no Transfer Factor was added. To further validate the test, the lab used a positive control. In this case, the positive control was the potent physiological immune mediator called interleukin 2 or IL-2. Interleukin 2 very specifically stimulates NK cell actions and, when used in drug form, is known as a standard for some types of cancer research. In the NK cell assay, IL-2 gave an 88% increase in cell lysis. Amazingly, 4Life Transfer Factor Plus Advanced Formula outperformed the positive control and was dubbed by the researchers as the “golden interleukin.”

Interleukin 2 is used in medicine for certain cancer patients. It is used in the hope that it will increase NK cell function and improve outcomes. Unfortunately, IL-2 is experimental, very expensive and can have rather toxic side effects when administered to patients. Both laboratory studies and human experience show that 4Life Transfer Factor and 4Life Transfer Factor Plus are non-toxic and well tolerated by animals and people alike. More than likely, these two products work to stimulate a natural release of immune modulators like the interleukins.

In the laboratory test, the highest-performing blend also revealed some new important information. The 4Life Transfer Factor blend followed a classic dose-response curve. Simply put, this means there is a dose of the blend in this assay that provides the optimum response. A smaller dose provides a lesser response and conversely a higher dose provides no additional benefit. Most nutritional supplements as well as prescription drugs function in the classic dose-response fashion.

Shown in Figure 2 is the actual data from the highest-performing blend. This somewhat complex piece of information gives scientists confidence in the NK cell assay and describes the dose-response character of 4Life Transfer Factor blend.

4Life Transfer Factor Plus Advanced Formula

4Life Transfer Factor Plus Advanced Formula increased NK cell lysis 437%, that’s nearly 450%, the maximum that this particular assay can measure. Just how this combination of ingredients works is not clear, yet the components are the subject of active research by molecular immunologists.

The additional components of 4Life Transfer Factor Plus Advanced Formula may account for the greater response over IL-2. The plant-based complex polysaccharides, like mannins and glucans, have the ability to interact with special receptors on other immune system cells. The macrophage and antigen processing cells (APC) activate in the presence of these plant materials. They appear to these cells as if they are products of bacteria or yeast. The interaction causes further release of stimulating cytokines. Thus, the two sources of stimulation synergize to give the high NK cell functions.

This type of immune stimulation is desirable, as it now appears from recent studies that a stimulated immune system is a high-functioning and balanced immune system. The concept of balance has great implication for regulation of immune functions that have gone astray.

In a matter of one day after a new viral infection, the cytokines are in action and soon thereafter, the NK cell activity increases and peaks. At this peak, the total viral load plateaus. This plateau is due to the action of the NK cells killing virally-infected cells and stopping replication of the virus.

It is now clear that early and effective NK cell function is critical and determines the outcome and duration of an illness.

Health Implications

Supplementing immune function and vigilance is now possible at a level unknown less than a decade ago. The paradigm shifts, as we have the ability to move the NK cell peak activity from hours to days earlier. The amazing implication is that with improved NK function, infection without illness is possible as is tumor recognition and destruction before the tumor becomes recognized as disease.

The opportunity to prevent illness has been rather illusive, except for the application of a few vaccines. The ability to safely and inexpensively improve immune function makes this hope no longer illusive. Prevention is indeed the key and available to everyone through transfer factor.

BAGAIMANA MENGHINDARI PENYAKIT DAN MELAWAN PENYAKIT.

ASSALAMMULAIKUM DAN SELAMAT SEJAHTERA KEPADA SESIAPA YANG MENBACA BLOG SAYA.

PERTAMA SEKALI INGIN SAYA MEMPERKENALKAN TRANFER FACTOR 4LIFE UNTUK ANDA DAN KELUARGA ANDA DAN KEGUNAAN DALAM KEHIDUPAN ANDA SEKELUARGA DALAM MENCEGAH DAN MEMBANTU MELAWAN PENYAKIT.

RAMAI YANG SERING BERTANYA KEPADA SAYA APA ITU TRANSFER FACTOR DAN KEGUNAAN UNTUK DIRI MEREKA DALAM MELAWAN PENYAKIT DAN MENCEGAH PENYAKIT.

DISINI SAYA TERANGKAN SIKIT LEBIH KURANG BERKENAAN TRANSFER FACTOR.

1) TRANSFER FACTOR ADALAH MOLEKUL PENGETAHUAN TENTANG  PENYAKIT PENYAKIT.

2) TRANSFER FACTOR TIDAK MENGUBATI PENYAKIT TETAPI MENDORONG SISTEM PERTAHANAN BADAN KITA MELAWAN PENYAKIT DENGAN MEMBERI IMUN SISTEM KITA ILMU DAN GAMBARAN TENTANG PENYAKIT.

3)TRANSFER FACTOR BUKAN PRODUK YANG MEMPERKUATKAN TETAPI MEMPERPANDAIKAN IMUN SISTEM KITA DALAM MELAWAN PENYAKIT.

4) PRODUK TRANSFER FACTOR ADALAH PRODUCT YANG MEMPUNYAI HAK MILIK(PATENTED) OLEH SYARIKAT 4LIFE.JADI UNTUK MENCUBA PASTIKAN ANDA DAPAT DARI PENGEDAR 4LIFE YANG SAH.

5) TRANSFER FACTOR BUKAN VITAMIN/MINERAL/HERBA ATAU SEBARANG PRODUK YANG ANDA TEMUI DI PASARAN MALAYSIA,IA ADALAH KATEGORI YANG BARLAINAN DARI APA YANG ANDA KETAHUI.(clik sini untuk lebih tahu)

6) DENGAN TRANFER FACTOR ANDA MELINDUNGI DIRI ANDA DARI PELBAGAI PENYAKIT KERANA TRANSFER FACTOR ADALAH ILMU PENGETAHUAN YANG DI AMBIL DARI SUSU AWAL LEMBU DAN KUNIG TELOR AYAM.

BAYANG KAN SENARIO INI..

MANUSIA/AYAM/LEMBU MEMINUM AIR DI SAWAH PADI ATAU PARIT…

MANUSIA/AYAM/LEMBU DIHINGGAPI DI HURUNGI LALAT DI MULUT…

MANUSIA/AYAM/LEMBU BERDIRI MELEBIHI 12 JAM SEHARI…

KENAPA AYAM DAN LEMBU TIDAK MENGALAMI SAKIT PERUT ATAU LAIN LAIN PENYAKIT WALHAL MEREKA PUN MINUM/MELAKU PERBUATAN SEPERTI MANUSIA DALAM SENARIO DI ATAS??

JAWAPAN NYA MUDAH..

KERANA IMUN SISTEM AYAM DAN LEMBU PUNYAI PENGETAHUAN DAN MENGENALI LEBIH BANYAK KUMAN/VIRUS DAN SEL ROSAK DAN 4LIFE RESEARCH MEMPUNYAI PATENTED TERHADAP BAGAIMANA UNTUK MENGESTRAK TRANSFER FACTOR DARI AYAM DAN LEMBU BERKENAAN PENYAKIT DAN APABILA KITA MENGAMBIL TRANSFER FACTOR KITA MEMPUNYAI PERLINDUNGAN YANG LEBIH DALAM MELAWAN PENYAKIT ATAU MENGUBATI PENYAKIT KERANA IMUN SISTEM KITA LEBIH BERPENGETAHUAN.

KITA KALAH DALAM PERJUANGAN MELAWAN PENYAKIT BUKAN SEBAB KEKUATAN,TETAPI PENGETAHUAN.

DENGAN ILMU KITA BOLEH MENCEGAH PENYAKIT.

DENGAN ILMU KITA BOLEH MENGUBATI PENYAKIT.

DENGAN ILMU KITA BOLEH MENOLONG ORANG.

DENGAN ILMU KITA BOLEH MENYEDARKAN ORANG.

IBRAHIM WINNERS4LIFEMELAKA

0163581794/0163153132

SEJARAH DI SEBALIK TRANSFER FACTOR.

The story of transfer factors and nanofractions

For more than a decade, 4Life® (the immune system company) has led the industry in immune system discovery and innovation. Where did it all begin? With the revolutionary molecules in your own body.

Transfer Factors

In 1996, 4Life Chief Executive Officer David Lisonbee came across a patent for the extraction of transfer factors. Transfer factors are molecules found within the immune systems of all mammals and birds. Dubbed “the memory molecules,” transfer factors serve as important components of the immune system throughout your entire life.

In 1998, 4Life licensed the patent to extract transfer factors from cow colostrum. In the years that followed, 4Life launched new products, stabilized transfer factors in liquid form, patented the extraction of transfer factors from chicken egg yolks, and combined our two sources for a truly synergistic formula.

Nanofractions

Scientists have known that smaller molecules than transfer factors existed within colostrum, but they never determined if they had any immune activity. In 2007, David Lisonbee and the 4Life Research and Development team isolated these nanofraction molecules, tested them, and determined their potential to support the immune system.

Nanofractions are low-weight molecules found in the immune systems of certain mammals and birds. They function as part of the “command and control” network of the immune system.

Transfer factors and nanofractions transfer immune memory, knowledge, and wisdom from one entity to another. The two most abundant and safest sources for transfer factors and nanofractions are cow colostrum and chicken egg yolks. Because these molecules aren’t species-specific, we can benefit from the knowledge gained by these animals during their lifetimes by transferring that knowledge from their immune cells to ours.

Be Smart. Be Speedy. Be Effective.

Your immune system relies on information. Specifically, it needs to know

(1) that there’s a problem and (2) how to deal with it.

The communication molecules of 4Life Transfer Factor keep your immune system informed and ready to respond. 4Life Transfer Factor helps your immune system act quickly, keeping your immune system in fighting form.

4Life Transfer Factor educates your immune system; it tracks the invaders you’ve encountered in the past and how your body dealt with them.

This history of success helps your immune system respond quickly and effectively to each new event.

Ibrahim winners4life melaka

click here to more knowledge about transfer factor

0163581794

PENTING!! KEPADA DOKTOR,PAKAR PERUBATAN DAN SESIAPA YANG PENTINGKAN ILMU KESIHATAN.

Trasylol (aprotinin injection)

Audience:
[UPDATE 05/14/2008] Following publication of the Blood conservation using antifibrinolytics: A randomized trial in a cardiac surgery population (BART) study in the May 14, 2008 online issue of The New England Journal of Medicine, Bayer Pharmaceuticals notified the FDA of their intent to remove all remaining supplies of Trasylol from hospital pharmacies and warehouses. Under a limited use agreement, access to Trasylol is limited to investigational use of the drug according to the procedures described in a special treatment protocol. The protocol allows treatment for certain patients who are at increased risk of blood loss and transfusions during coronary artery bypass graft surgery and who have no acceptable alternative therapy. Physicians using Trasylol in this situation must also verify that the benefits of the drug clearly outweigh the risks for their patients.

[Posted 11/05/2007] FDA announced that, at the agency’s request, Bayer Pharmaceuticals Corp. has agreed to a marketing suspension of Trasylol (aprotinin injection), a drug used to control bleeding during heart surgery, pending detailed review of preliminary results from a Canadian study that suggested an increased risk for death. FDA requested the suspension in the interest of patient safety based on the serious nature of the outcomes suggested in the preliminary data. FDA has not yet received full study data but expects to act quickly with Bayer, the study’s researchers at the Ottawa Health Research Institute, and other regulatory agencies to undertake a thorough analysis of data to better understand the risks and benefits of Trasylol.

Until FDA can review the data from the terminated study it is not possible to determine and identify a population of patients undergoing cardiac surgery for which the benefits of Trasylol outweigh the risks. However, understanding that individual doctors may identify specific cases where benefit outweighs risk, FDA is committed to exploring ways for those doctors to have continued, limited access to Trasylol. There are not many treatment options for patients at risk for excessive bleeding during cardiac surgery. Thus, FDA is working with Bayer to phase Trasylol out of the marketplace in a way that does not cause shortages of other drugs used for this purpose.

[May 14, 2008 - Drug Information Page - FDA]
[May 14, 2008 - FDA News - FDA]
[November 5, 2007 - FDA News - FDA]

Previous MedWatch Alert:

[October 25, 2007]

Trasylol Deaths & Injuries – Drug Side Effects and Recall

Thought to be the next billion-dollar drug for pharmaceutical giant Bayer, Trasylol was designed to control bleeding during heart surgery. As early as the 1980s, warnings from drug researchers indicated that the drug may cause deadly side effects. However, these reports did not derail Bayer’s tenacious pursuit of FDA approval and worldwide distribution of Trasylol. The negligent release of Trasylol despite health warnings has caused thousands of patients worldwide to suffer serious injury and/or death. The personal injury lawyers and wrongful death attorneys at Phillips & Associates are dedicated to helping injured victims and their families file lawsuits against Bayer in order to obtain justice and rightful financial compensation.

SENARAI PENYAKIT YANG BOLEH MENCUBA TRANSFER FACTOR 4 LIFE.

Assalammulaikum dan selamat sejahtera,

Sekiranya anda mempunyai penyakit seperti di bawah, Saya syorkan anda mencuba Tranfer Factor 4life.

TETAPI SEBELUM ANDA MENCUBA,SAYA JUGA SYORKAN ANDA UNTUK MEMBACA BLOG SAYA SEPENUHNYA BERKENAAN TRANSFER FACTOR DAN KEGUNAANNYA.

SENARAI PENYAKIT YANG BOLEH MENCUBA TRANFER FACTOR 4LIFE.

• Allergi/ Alahan • Infeksi Liver • Arthritis • Step • Denggi • Vertigo • Autism • HIV • Migraine • Herpes • Campak • Gastrik • Batuk • Hepatitis • Infeksi Virus

• Kanser/Tumor • Diabetes 1 & 2 • Penyakit jantung • Darah tinggi • Penyakit² kulit • Buah pinggang • Asthma/ Semput • Alzheimer’s • Parkinson’s • Lupus/ SLE • Demam/ Flu • Gout/ Pirai • Tuberculosis (TB) • Resdung / Sinus Bisa badan

Bird Flu HFMD / SARS Multiple Sclerosis Parasitic diseases Autoimmune diseases Mycobacterial diseases Fungal diseases Malignant diseases Neurological diseases Bacterial diseases Bronchitis Obesity/ Gemuk Infeksi mata / rabun Infeksi usus Infeksi paru-paru

IBRAHIM.WINNER4LIFEMELAKA

HP: 0163581794

www.ibrahim.bscard.info

KITA HANYA MENCUBA,TETAPI YANG ESA MENENTUKAN KEPUTUSANNYA.

MAKANAN KESIHATAN 4LIFE DAN APA KANDUNGANNYA.

4Life Transfer Factor® Tri-Factor™ Formula:

Transfer Factor

E-XF™ (a patented concentrate of transfer factors from cow

colostrum and egg yolk).

4Life Transfer Factor Plus® Tri-Factor Formula:

Zinc, Transfer Factor E-XF (a patented concentrate of transfer factors

from cow colostrum and chicken egg yolks), Cordyvant

Polysaccharide Complex (IP-6, Soya Bean Extract, Cordyceps

sinensis, Beta-Glucans, Agaricus Blazeii, Mannans, Olive Leaf,

Maitake Mushroom, Shiitake Mushroom).

4Life Transfer Factor RioVida® Tri-Factor Formula:

Vitamin C,Transfer Factor E-XF, RioVida Juice Blend (Acai, Pomegranate,

Blueberry, Elderberry, Grape, Apple), Lactoferrin, Natural

Preservatives.

4Life Transfer Factor Belle Vie®:

Targeted Transfer Factor

(a patented extract containing Targeted Transfer Factor from cow

colostrum and egg yolk), Phytoestrogen Proprietary Blend,

Kudzu Isoflavone Extract, Red Clover Isoflavone Extract, Flax

Lignan Extract, Cruciferous Vegetable Blend (blend contains

broccoli, cabbage, and kale along with Indole 3-Carbinol,

Diindoly Methane (DIM), Ascorbigen and other dietary indoles),

Green Tea Extract (catechins), Calcium d-Glucarate, Grapeseed

Extract, Clove oil, Gelatin, Glycerin, Water.

4Life Transfer Factor Cardio™:

Cardio Targeted Transfer Factor

(a proprietary extract containing Targeted Transfer Factor from

egg yolks), Vitamin A, Vitamin C, Vitamin E, Niacin, Vitamin

B6, Folate, Vitamin B12, Magnesium, Zinc, Selenium, Copper,

Potassium, Proprietary Blend (Butchers Broom, Ginkgo Biloba,

Hawthorn, Garlic, Coenzyme Q10, Red Rice Yeast Extract,

Resveratrol and Ginger Oil).

4Life Transfer Factor Chewable:

Transfer Factor E-XF (a patented concentrate of transfer factors from cow colostrum

and egg yolk).

BERMINAT UNTUK MENCUBA?

HUBUNGI

ZAIDAH WINNERS4LIFE MELAKA.

016-3153132

EMAIL :help_linemy@hotmail.com